BOJI CRO: "FCZR" has received the drug clinical trial approval notice
I'm PortAI, I can summarize articles.
BOJI CRO recently announced that its application for "FCZR" has received the clinical trial approval notice from the National Medical Products Administration. FCZR is a modified new drug targeting ear fungal disease, with significant clinical advantages. The drug's formulation and administration method have been optimized for ear drop application, allowing it to directly act on the ear canal lesions. Currently, there are no similar drugs approved for marketing domestically or internationally
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments